ArticleBMC neurology2025
Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytokine Changes With Effective Drug Therapy for Juvenile Myasthenia Gravis.Journal of immunology research · 2026Article
- Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. Increasing evidence has suggested inflammation is involved in the pathogenesis of MG, but whether it is the cause or a downstream effect remains unclear. In this study, a two-sample Mendelian randomization (TSMR) analysis was performed to explore the causal relationship between 91 circulating inflammatory cytokines and MG.
methodIn this study, the data of 91 circulating inflammatory cytokines from 4824 Europeans and the largest GWAS database of MG (1873 patients and 36370 controls) were used to screen instrumental variables (IVs). Inverse variance weighting (IVW), Bayesian weighted MR (BWMR), MR-Egger regression, weighted median (WM), simple mode and weighted mode were used to evaluate the association between MG and inflammatory cytokines. The MR-Egger intercept test and Cochran's Q test were used to test the pleiotropy and heterogeneity of IVs.
resultOur results showed that adenosine deaminase (ADA) and CD40 Ligand (CD40L) are positively associated with the risk of MG (OR = 1.16, 95%CI: 1.00-1.33, P = 0.041; OR = 1.20, 95%CI: 1.02-1.40, P = 0.025), while interleukin-1-alpha (IL-1α), glial-cell-line-derived neurotrophic factor (GDNF), Osteoprotegerin (OPG) and tumor necrosis factor-beta (TNF-β) are negatively associated with the risk of MG (OR = 0.80, 95% CI: 0.64 ~ 0.99, P = 0.042; OR = 0.74, 95%CI:0.58 ~ 0.0.96, P = 0.022; OR = 0.76, 95% CI: 0.61 ~ 0.94, P = 0.013; OR = 0.76, 95% CI: 0.61 ~ 0.94, P = 0.012; OR = 0.80, 95% CI: 0.68 ~ 0.93, P = 0.006). In addition, genetically predicted MG affected the expression of seven cytokines. Sensitivity analysis showed no horizontal pleiotropy and significant heterogeneity of all results.
conclusionsOur results provided promising clues for the treatment of MG. We evaluated the association between inflammatory cytokines and the disease by genetic informatics approach, which may help to better understand the underlying mechanisms of MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.